InMed Pharmaceuticals (NASDAQ:INM) Trading 2.6% Higher – Still a Buy?

Posted by Francis Steltz on Jul 2nd, 2026

InMed Pharmaceuticals Inc. (NASDAQ:INM – Get Free Report) shares rose 2.6% during mid-day trading on Wednesday . The stock traded as high as $1.59 and last traded at $1.59. 57,764 shares changed hands during trading, an increase of 6% from the average session volume of 54,301 shares. The stock had previously closed at $1.55.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of InMed Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to MarketBeat, InMed Pharmaceuticals currently has a consensus rating of “Sell”.

Check Out Our Latest Stock Analysis on INM

InMed Pharmaceuticals Stock Up 2.6%

The firm has a fifty day simple moving average of $1.26 and a 200-day simple moving average of $1.06. The company has a market cap of $5.26 million, a PE ratio of -0.55 and a beta of 0.95.

InMed Pharmaceuticals (NASDAQ:INM – Get Free Report) last announced its earnings results on Wednesday, May 6th. The company reported ($0.69) EPS for the quarter, beating analysts’ consensus estimates of ($94.44) by $93.75. InMed Pharmaceuticals had a negative net margin of 132.87% and a negative return on equity of 80.85%.

Insider Buying and Selling at InMed Pharmaceuticals

In other InMed Pharmaceuticals news, major shareholder Adar1 Capital Management, Llc purchased 468,551 shares of InMed Pharmaceuticals stock in a transaction dated Tuesday, May 19th. The stock was acquired at an average cost of $1.54 per share, with a total value of $721,568.54. Following the acquisition, the insider directly owned 800,000 shares of the company’s stock, valued at $1,232,000. This represents a 141.36% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Vivo Opportunity, Llc bought 56,210 shares of the firm’s stock in a transaction on Wednesday, May 20th. The shares were bought at an average price of $1.56 per share, for a total transaction of $87,687.60. Following the completion of the transaction, the insider directly owned 543,129 shares in the company, valued at approximately $847,281.24. This represents a 11.54% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 717,778 shares of company stock worth $1,113,123 over the last three months. 0.85% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On InMed Pharmaceuticals

A hedge fund recently bought a new stake in InMed Pharmaceuticals stock. Virtu Financial LLC purchased a new stake in InMed Pharmaceuticals Inc. (NASDAQ:INM – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 20,369 shares of the company’s stock, valued at approximately $45,000. Virtu Financial LLC owned approximately 0.73% of InMed Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 20.12% of the company’s stock.

About InMed Pharmaceuticals

(Get Free Report)

InMed Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Vancouver, British Columbia, that is dedicated to the discovery and development of novel therapeutics derived from cannabinoids. Leveraging a proprietary drug discovery engine, the company works to identify, design and optimize cannabinoid-based molecules with the goal of addressing diseases that have significant unmet medical needs. InMed’s integrated business model combines research, development and manufacturing capabilities under one roof to streamline the progression of promising assets from preclinical studies into human trials.

The company’s pipeline features multiple lead programs targeting both neurological and dermatological disorders.